DOLF investigators are beginning a follow-up study on the efficacy of a new combination treatment for lymphatic filariasis (LF) and onchocerciasis in the Akoupé district of Côte d’Ivoire. This study began July 4th and builds upon a large-scale community survey sponsored by Medicines Development for Global Health (MDGH).
DOLF Initiating a Follow Up Study on Moxidectin plus Albendazole (MoxA) Combination Treatment for Lymphatic Filariasis and Onchocerciasis in Cote d’Ivoire
View Content